Introduction
Waldenström macroglobulinemia (WM) is a mature B-cell disease, the genetic bases of which are poorly understood. Few recurrent chromosomal abnormalities have been reported in WM, partly owing to difficulties in obtaining tumor metaphases for karyotyping. Alternative techniques such as fluorescence in situ hybridization (FISH) have also been used to study this disease. Deletion of the long arm (q) of chromosome 6 is the most common abnormality, being found in up to 50% in patients. To address these issues, we conducted a cytogenetic study of a large series of untreated symptomatic patients enrolled in a prospective, randomized, open-label clinical trial. The WM1 study took place in 101 centers in 5 countries and enrolled 339 patients with WM, 37 patients with non-MALT marginal zone lymphoma (MZL), and 38 patients with lymphoplasmacytic lymphoma, who were all randomly assigned to receive chlorambucil or fludarabine. (7) Here we report our cytogenetic findings in 174 of the WM patients enrolled in this trial.
Design and Methods

Patients and WM1 study
Patients ≥18 years old with previously untreated WM and an Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2 were eligible. Inclusion required an established diagnosis of WM requiring treatment with a CD20+, CD5-, CD23-, CD10-tumor-cell immunophenotype. Patients were assigned to oral chlorambucil 8 mg/m²/d (6 mg/m²/d if >75 years old) for 10d every 28d for a maximum of 12 cycles, or to oral Overall survival (OS) was measured from enrollment to death or the last follow-up visit.
Progression-free survival (PFS) was measured from enrollment to disease progression, death from any cause, or the last follow-up visit. Disease-free survival (DFS) was measured from the date of response until disease progression or death. Distributions of OS, PFS and DFS were estimated with the Kaplan-Meier method and compared using the log-rank test. (9, 10) All tests were two-sided. An effect was considered statistically significant if the p value was 0.05 or less. The SAS 9.2 (SAS, Inc., NC) and R 2. 
Results
Clinical results
The M/F sex ratio was 2. 
Conventional cytogenetic (CC) and FISH analyses
CC was successful in 141/172 cases (82%), of which 66 (47%) showed clonal abnormalities (see Table 1 ). Twenty (30%) of the 66 abnormal CCs were complex, with at least three chromosomal changes, and 23 (35%) showed translocations (5 balanced and 18 unbalanced). A t(11;18)(q21;q21) translocation involving MALT1 was observed in one case. Twenty (30%) of these 66 abnormal CCs included loss of sex chromosomes, and this was an isolated abnormality in six patients. Since the loss of sex chromosome is common in elderly patients, it may represent a non-specific finding in WM. Table 1 ). Deletion of 17p was only detected by FISH in four patients (three with a normal karyotype and one with a complex karyotype with 2 markers) ( Table 2 ). Deletion of 17p was observed in the dominant clone of four patients and in a subclone from one patient. Among 7 patients with a translocation, 3 (43%) had a 17p deletion vs 4/86 (5%) patients without translocation (p=0.03) (Supplementary Table 1 ).
When associated with another FISH abnormality, 17p deletion affected a lower proportion of cells in four patients and the same proportion in two patients. Of note, patients with 17p deletion had a higher percentage of tumor cells in their bone marrow than patients without 17p deletion (median 77% vs 46%, p=0.01).
Correlations with prognostic factors
Cytogenetic profiles were comparable across the two treatment arms. The observed chromosomal abnormalities were analyzed with respect to the adverse characteristics included in the International Scoring System for WM (ISSWM), namely age >65 years, hemoglobin (Hb) <11.5 g/dL, platelet count <100x10 9 
TP53 gene sequencing
Finally, we analyzed TP53 sequences (exons 4-10) in three patients with 17p deletion in 13%, 17% and 52% of interphase nuclei (FISH analysis). No mutations were detected.
Discussion
The The minimal deleted region on 13q14 seems to be similar in WM and CLL, and includes the microRNA genes miRNA-15a and miRNA-16-1.(6, 25) Deletion of 13q14, when isolated, is associated with a good prognosis in patients with CLL but seems to be associated with disease progression in MM. (16, 22) In contrast, this abnormality had no influence on outcome and was not associated with adverse characteristics in our series of WM. It has been suggested that 13q14 deletions usually arise at the time of disease progression in WM,(4) but we found some 13q deletions shortly after diagnosis.
We confirm our previous results regarding the occurrence of trisomy 4 in WM (8%), and we show that trisomy 4 is significantly associated with trisomy 18 in our series. The frequency of 11q22 (ATM) deletions is 7-24% in CLL, and this abnormality is often associated with lymphadenopathy and a poor prognosis. (14, 22, 26) In our series of WM, 11q deletion was associated with advanced age and hypoalbuminemia but had no impact on clinical outcome. Deletion of 17p is associated with TP53 mutation in about 80% of CLL patients. Although CLL with 17p deletion but without TP53 mutation is rare, it carries a poor prognosis. (27) In MM, 63% of 17p deletions are not associated with TP53 mutation. The reported frequencies of trisomy 12 are 11-15% in CLL and 8-15% in MZL. (18, 22) This abnormality is often associated with an atypical morphology and has a controversial prognostic influence in CLL. (22, 30) Trisomy 12 was very rare in our series of WM patients (<5%), and was significantly associated with short PFS. When adjusting for treatment arms and the ISSWM risk groups, trisomy 12 was still associated with shorter PFS. In contrast, it did not influence overall survival. Trisomy 12 may reflect a particular aspect of sub-types of B-cell disorders that warrant further investigations.
In 
